Application of (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide in the control of fungal diseases in crops
By targeting the phase separation interface of Rhizoctonia solani RsYTHDC protein, a small molecule compound (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide was developed and prepared into a pesticide composition, which solved the problem of poor control effect of Rhizoctonia solani in the existing technology and achieved a highly efficient and safe disease control effect.
Patent Information
- Application Number
- CN202611540341.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-30
- Publication Date
- 2026-11-17
AI Technical Summary
Existing chemical fungicides are not very effective in controlling Rhizoctonia solani disease. The pathogen has developed serious resistance to the fungicide, and the target is singular, making it difficult to develop effective drugs through structural design.
Develop a small molecule compound (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide to target the phase separation interface of RsYTHDC protein in Rhizoctonia solani, interfering with its pathogenicity, and prepare it into pesticide compositions such as emulsifiable concentrates and suspensions for the control of crop sheath blight.
It significantly inhibits the disease symptoms of Rhizoctonia solani, with a control efficacy of ≥47.2%, has no adverse effect on crop yield, has a broad-spectrum antibacterial effect, delays the development of drug resistance, and is in line with the development direction of green pesticides.
Smart Images

Figure CN123100617A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the application of small molecule inhibitors in the control of fungal diseases in crops, and particularly to (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide in the control of fungal diseases caused by Rhizoctonia solani (…). Rhizoctonia solani The application of (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide in the prevention and control of plant diseases is described in this context. Background Technology
[0002] Sheath blight caused by Rhizoctonia solani is a major disease affecting key grain crops such as rice, wheat, and corn, often leading to severe yield reductions. Currently, treatment mainly relies on traditional chemical fungicides such as benzimidazoles and sterol demethylation inhibitors; however, the pathogen's resistance is becoming increasingly serious, and new drug development cycles are long and often target only a single organism.
[0003] Most fungal effector proteins lack the classic deep-cavity binding pocket, making structure-based rational drug design difficult. Recent studies have shown that phase separation of biomolecules plays a crucial role in various life activities, and pathogen effector proteins can also interfere with host cell function through phase separation mechanisms. For example, the Fusarium oxysporum effector protein FolSvp2 hijacks plasmid SlISP into effector condensates within plant cells through phase separation, reducing host ROS production and subsequently causing tomato wilt.
[0004] However, in the field of plant fungal disease control, the use of small molecules to intervene in the phase separation behavior of fungal effector proteins is still a blank. Therefore, discovering such novel targets and developing corresponding inhibitors is of great significance for the innovation of antifungal drugs. Summary of the Invention
[0005] The main objective of this invention is to discover small molecule compounds that have a significant inhibitory effect on crop diseases caused by fungi such as Rhizoctonia solani.
[0006] The above-mentioned objectives of the present invention are mainly achieved through the following technical solutions: One aspect of this invention is the application of (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide in the preparation of a treatment for the pathogenic bacterium Rhizoctonia solani ( ). Rhizoctonia solani A pesticide formulation for crop sheath blight caused by fungi; wherein the molecular formula of (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide is C 24 H 29 Br2N2O4 has the following chemical structural formula: Formula I Another aspect of the present invention is to provide a pesticide composition for combating crop diseases caused by Rhizoctonia solani fungi, comprising (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide and a pesticide formulation using an acceptable carrier.
[0007] The carrier can be a conventional carrier in pesticide formulations, such as a wetting and dispersing agent, stabilizer, emulsifier, thickener, antifreeze agent, preservative, disintegrant, binder, or filler. For example, the wetting and dispersing agent can be one or a mixture of two or more of sodium dodecyl sulfate, BX (a dispersing agent), or alkylphenol polyoxyethylene ether in any proportion. The filler can be kaolin, etc.; the emulsifier can be one or more of the nonionic surfactant castor oil ethylene oxide adduct, nonylphenol polyoxyethylene ether, or fatty alcohol polyoxyethylene ether. The thickener can be one or more of xanthan gum, carboxymethyl cellulose, magnesium aluminum silicate, or attapulgite. The antifreeze agent can be any one of ethylene glycol, propylene glycol, glycerol, or glycerol-ethyl ether diethylene glycol. The stabilizer can be any one of 2,6-di-tert-butyl-4-methylphenol, citric acid, or butylated hydroxyanisole (BHA). The disintegrant can be any one or more of urea, montmorillonite, or bentonite. The adhesive may be one or more of gelatin, xanthan gum, or gum arabic.
[0008] (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide and a carrier for pesticide formulations can be prepared into various pesticide formulations using conventional pesticide formulation methods, such as emulsifiable concentrates, suspensions, wettable powders, water-dispersible granules, microemulsions, water-in-oil emulsions, oil suspensions, emulsifiable concentrates, etc., preferably emulsifiable concentrates or water-dispersible granules; the preparation methods of these pesticide formulations are well known to those skilled in the art.
[0009] For reference, the present invention provides a method for preparing the pesticide composition into a water-dispersible granule, comprising: mixing and pulverizing (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide with wetting agent, dispersant, filler, etc., then adding water and kneading, and then adding the mixture to a granulator for granulation, and then drying and sieving to obtain the water-dispersible granule product.
[0010] For reference, the present invention provides a method for preparing the pesticide composition into a wettable powder, comprising: thoroughly mixing (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide with various adjuvants and fillers, pulverizing the mixture using an ultrafine pulverizer, and then mixing the mixture evenly to obtain a wettable powder.
[0011] In a preferred embodiment of the present invention, the *Rhizoctonia* genus ( Rhizoctonia solaniThe preferred fungus is Rhizoctonia solani ( ). Rhizoctonia solani ).
[0012] In a preferred embodiment of the present invention, the crop includes buckwheat, corn, wheat or barley.
[0013] The application concentration of the pesticide composition described in this invention is 2.5-20 μg / mL for in vitro application and 0.1-1% (w / v) aqueous solution for foliar spraying in the field, with a frequency of 1-2 times per week.
[0014] To determine the phase separation ability of the RsYTHDC protein and its key role in pathogenicity, this invention expressed the coding gene sequence (SEQ ID No. 2) of Rhizoctonia solani Rs. solani (SEQ ID No. 1) in prokaryotes to obtain crude protein. After purification, a soluble His-tagged protein was obtained. The purified RsYTHDC protein was incubated in phase separation buffer at room temperature. Observation under a differential interference contrast microscope confirmed that the formed aggregates exhibited typical liquid flow characteristics, indicating liquid-liquid phase separation. To verify its phase separation ability in vivo, the constructed RsYTHDC-GFP fusion expression plasmid was transiently transformed into buckwheat leaf protoplasts via PEG-mediated transformation. Twenty-four hours after transformation, under a confocal microscope, numerous dynamic, droplet-like fluorescent aggregates of RsYTHDC-GFP were observed in the cytoplasm. In contrast, the mutant RsYTHDC lacking the intrinsic disorder region (PrD) domain... ΔPrD -GFP was uniformly dispersed without aggregate formation, confirming that the PrD domain is essential for phase separation.
[0015] To confirm the direct link between phase separation ability and pathogenicity, this invention further overexpresses [the substance] in Arabidopsis thaliana. RsYTHDC Genes, compared to wild type, are overexpressed RsYTHDC Arabidopsis thaliana (OE-) RsYTHDC Disease resistance is significantly reduced; while overexpression RsYTHDC ΔPrD The disease resistance of the mutant Arabidopsis thaliana was not significantly different from that of the wild type; the above results together demonstrate that the RsYTHDC protein has a significant phase separation ability and that this ability is key to its pathogenic function.
[0016] Based on the elucidated pathogenic mechanism of RsYTHDC phase separation, this invention conducted screening, discovery, and binding verification experiments of small molecule inhibitors targeting the RsYTHDC phase separation interface. First, AlphaFold 3 software was used to predict the high-confidence three-dimensional structure of the RsYTHDC protein. By analyzing the surface features of its key phase separation interface—the YTH domain—a binding pocket containing key residues such as Phe534, Asp537, Tyr589, and Arg631 was defined as a virtual pharmacodynamic pocket for screening. Subsequently, Autodock was used... The Vina molecular docking program was used to perform high-throughput virtual screening of a commercial molecular library containing approximately 1.6 million compounds. After two rounds of docking screening with increasing precision, combined with molecular dynamics simulations to evaluate the binding conformational stability, compound sdf:12041 (chemical name: (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide) was ultimately ranked as the top-ranked candidate lead compound. To verify the results of the virtual screening, micro-thermophoresis was used to directly measure the binding ability of sdf:12041 to RsYTHDC protein. The experimental results showed that the binding of sdf:12041 to RsYTHDC exhibited a significant concentration dependence, and the dissociation constant Kd was obtained as 17.51 using the instrument's software. nM confirmed its strong affinity at the nanomolar level, a result highly consistent with the predictions of virtual screening; to further confirm the binding specificity of sdf:12041, a point mutant of the YTH domain of RsYTHDC (RsYTHDC) was constructed. mut The mutant altered key residues in the predicted binding pocket. Binding assays using the same MST method showed a sharp decrease in the binding affinity of sdf:12041 to the mutant protein. This control experiment demonstrated that sdf:12041 indeed specifically binds to the calculated predicted YTH domain functional interface of RsYTHDC. Finally, through the aforementioned integrated computational biology and biophysical experimental process, a small molecule inhibitor (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide (sdf:12041) capable of binding to the key phase-separation interface of RsYTHDC with high affinity and specificity was successfully screened and identified.
[0017] This invention further elucidates the molecular mechanism by which sdf-12041 inhibits the phase separation of RsYTHDC based on molecular dynamics simulations. The simulation results reveal the mechanism of action of sdf-12041 at the atomic scale: sdf-12041 specifically binds to the interface residues of the YTH domain of RsYTHDC, disrupting its intramolecular interaction network with PrD2 / 3 / 4, thereby stabilizing the non-phase-separating conformation of the protein and ultimately inhibiting its liquid-liquid phase separation ability. This discovery provides conclusive structural biology evidence for sdf-12041 as a targeted inhibitor of phase separation.
[0018] Field trials on the control of buckwheat sheath blight showed that the sdf-12041 treatment group exhibited significant control effects against buckwheat sheath blight, with its efficacy being significantly superior to the disease control group (P<0.001). Further experiments revealed that sdf-12041 also demonstrated good control efficacy against Rhizoctonia solani in maize, wheat, and barley, indicating that sdf-12041 has a broad-spectrum antibacterial effect against crop diseases caused by Rhizoctonia solani.
[0019] To comprehensively assess the safety of compound sdf-12041 for crops, yield determination and metabolomics analysis were conducted at harvest. Yield determination results showed no significant difference in crop yield between the sdf-12041-treated area and the healthy control group, while the yield of the diseased control group was significantly reduced. Non-targeted metabolomics analysis (LC-MS) revealed that the levels of core metabolites (including sugars, amino acids, and organic acids) in the leaves of the treated crop were highly similar to those of the healthy control group, with a low proportion of differentially metabolites, mainly concentrated in secondary metabolic pathways such as terpenes and lignin, while primary metabolic pathways remained largely unaffected. Furthermore, transcriptomics analysis showed that the proportion of gene expression changes induced by sdf-12041 treatment was low, and it did not significantly enrich in key growth-related pathways. Tissue distribution analysis showed that the compound was systematically transported to roots, stems, and other organs after foliar spraying, indicating good systemic translocation.
[0020] In summary, this invention discovers that the small molecule inhibitor (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide can inhibit the phase separation of the toxic protein RsYTHDC, thereby alleviating the symptoms of crop sheath blight caused by the pathogenic fungus Rhizoctonia solani. The inhibitor's mechanism of action is novel; it does not directly kill the fungus but interferes with its pathogenicity, potentially delaying the development of resistance. Field trials have confirmed that this small molecule inhibitor has a control efficacy of ≥47.2% (based on a reduction in the disease index) against sheath blight in gramineous crops, while having no adverse effects on crop yield and metabolic homeostasis, and does not interfere with core metabolism, demonstrating good safety for agricultural application. It aligns with the development direction of green pesticides and has broad application prospects in the prevention and control of various plant diseases caused by Rhizoctonia solani. Attached Figure Description
[0021] Figure 1 Characterization of the phase separation properties of RsYTHDC protein and results of fluorescence bleaching recovery (FRAP) analysis of RsYTHDC-GFP condensates; (a) Schematic diagram of the three-dimensional structure of RsYTHDC and its variants, drawn based on AlphaFold3 prediction results; (b) Microscopic image of RsYTHDC protein phase separation condensates under sdf:12041 treatment; (c) Time-lapse imaging of the real-time dynamic fusion process of RsYTHDC-GFP condensates; (d) Time series image of the FRAP process; (e) Quantitative analysis curve of fluorescence recovery and quantitative statistical graph of fluorescence intensity recovery.
[0022] Figure 2 The results of functional verification of RsYTHDC phase separation in pathogenicity; (a) RsYTHDC-GFP fusion protein forms phase-separated condensates in plant protoplasts, while mutants lacking the PrD domain (RsYTHDC) ΔPrD (a) Confocal microscopy image showing diffuse distribution of GFP; (b) Overexpression RsYTHDC It significantly reduced Arabidopsis thaliana resistance to Rhizoctonia solani, while overexpression RsYTHDC ΔPrD A statistical comparison chart showing no significant change in the disease index of the plants.
[0023] Figure 3 Results of screening, binding verification, and mechanism of action of sdf:12041; (a) Computer simulation docking diagram of the binding pocket of sdf:12041 and the RsYTHDC YTH domain, with key interacting residues marked; (b) Root mean square deviation (RMSD) of the sdf:12041-RsYTHDC complex over time, indicating stable binding conformation; (c) Binding curve and dissociation constant (Kd) of sdf:12041 and wild-type RsYTHDC protein determined by microthermophoresis (MST); (d) sdf:12041 and the RsYTHDC point mutant (RsYTHDC... mut The binding curve of ) confirms its binding specificity.
[0024] Figure 4 The results of the field efficacy and safety assessment of sdf:12041 are shown; (a) shows the effects of different concentrations of sdf:12041 on buckwheat ( F. tataricum ) blades R. solani Phenotypic of AG4-HGI3 infection: detached leaves of 20-day-old seedlings were pretreated with 0%, 0.1%, 0.5%, and 1% sdf:12041, respectively. After inoculation with mycelial blocks, the samples were cultured at 30℃ for 36 hours. The figure shows a representative photograph of a single independent experiment, with a scale bar of 1 cm; (b) [The text abruptly ends here, likely due to an incomplete sentence or missing information.] Figure 4 Quantitative verification of the a-phenotype involved pretreatment of detached buckwheat leaves with 0.1%, 0.5%, and 1% SDF:12041, using untreated (CK) leaves as a control. R. solani AG4-HGI3 Data were obtained from three independent experiments, with 30 leaves per treatment group per experiment. Two-tailed Student's t-test showed that ** represented P < 0.01; *** represented P < 0.001; (c) The test was extended to maize (Zea mays), wheat (Triticum aestivum), and barley (Hordeum vulgare), with detached leaves treated with 1% sdf:12041 or untreated (control), and inoculated. R. solani After incubating AG4-HGI3 mycelial blocks for 72 hours, the experiment was independently repeated three times; (d) This panel is for Figure 4 Quantitative analysis of c was conducted on maize, wheat, and barley. Exvial leaves were pretreated with 1% sdf:12041 (grey bar chart) or water (Mock, black bar chart) before inoculation with the pathogen. Disease incidence was expressed as mean ± standard deviation (n≥30 leaves). Two-tailed t-test results showed highly significant differences between the three crop treatment groups and the control group (** represents P<0.01), indicating that sdf:12041 has a significant effect on the disease incidence of gramineous crops. R. solani Leaf infection showed significant protective efficacy; (e) Quantitative detection results of sdf:12041 accumulation and distribution in buckwheat plants by liquid chromatography-mass spectrometry (LC-MS) were presented. Soil-grown plants were treated with 1% sdf:12041 for 24 hours (Treat) or with DMSO as a control (CK). Subsequently, the sdf:12041 content in root, stem, and leaf tissues was measured. Data represent mean ± SD (n=3 biological replicates). Asterisks indicate statistical significance (** represents P<0.01; *** represents P<0.001, two-tailed Student's t test); (f) Field cross-inoculation trial conducted in Beijing was presented to evaluate the control efficacy of sdf:12041 against damping-off disease. The central schematic diagram indicated the two treatment areas: control (CK, R. solani + 1% DMSO) and treatment (sdf:12041 + R. solani), the figure shows representative symptom photos 1 week after vaccination.
[0025] Figure 5 Field yield assessment of buckwheat treated with sdf:12041 at two geographical experimental sites (Beijing and Zhaotong); Figure a shows the yield of buckwheat without sdf:12041. R. solaniUnder R. solani infection conditions, the final yield of tartary buckwheat at the Beijing field experimental site showed no significant change in yield compared to the control group (CK) after application of sdf:12041. Data are expressed as mean ± standard deviation (SD) (n=3), and ns indicates no significant difference (two-tailed Student's t-test). Figure b shows the final yield of tartary buckwheat at the Zhaotong, Yunnan field experimental site without R. solani infection. Compared to the control group (CK), the yield after application of sdf:12041 showed no significant change in yield. Data are expressed as mean ± SD (n=3), and ns indicates no significant difference (two-tailed Student's t-test). Figure c shows the yield of tartary buckwheat at the Beijing field experimental site under R. solani infection and sdf:12041 treatment. R. solani Processing group ( R. solani The yield of the treatment group was significantly lower than that of the buffer control group. Adding sdf:12041 significantly alleviated the yield inhibition caused by the pathogen. Data are expressed as mean ± SD (n=3), with lowercase letters above the bars indicating significant differences within groups (P>0.05, Tukey's HSD). Figure d shows... R. solani Results of buckwheat yield at a field experiment site in Zhaotong, Yunnan Province, under infection and SDF:12041 treatment. R. solani The yield in the treatment group was significantly lower than that in the buffer control group. Adding sdf:12041 significantly alleviated the yield inhibition caused by the pathogen. Data are expressed as mean ± SD (n=3). Lowercase letters above the bars indicate significant differences within the groups (P>0.05, Tukey's HSD).
[0026] Figure 6 Transcriptomic analysis of tartary buckwheat treated with sdf:12041; a) Bubble chart of GO functional enrichment analysis of differentially expressed genes (DEGs) in the transcriptome. RNA-seq was performed on 12-day-old tartary buckwheat seedlings treated with 1% sdf:12041. The analysis showed that DEGs were significantly enriched in secondary metabolic processes and stimulus responses; b) Bubble chart of KEGG pathway enrichment analysis of differentially expressed genes (DEGs) in the transcriptome. The results showed that the differentially expressed genes significantly activated the biosynthesis of plant secondary metabolites (especially phenylpropane and flavonoid biosynthesis) and plant hormone signal transduction pathways.
[0027] Figure 7Metabolomics analysis of tartary buckwheat treated with sdf:12041; a) is a distribution map of the folding changes of differential metabolites in the metabolome. Metabolomics analysis was performed on the whole tartary buckwheat plant treated with sdf:12041. Blue dots in the figure represent significantly differential metabolites (log2FC>1, P<0.05). The pie chart at the bottom shows the proportion of significantly changed and unchanged metabolites in each type of metabolite; b) is a bubble chart of KEGG pathway enrichment analysis of differentially accumulated metabolites in the metabolome. The analysis revealed a significant shift in metabolism towards alkaloid biosynthesis (indole and isoquinoline alkaloids) and sugar metabolism (amino sugar, nucleotide sugar and galactose metabolism), suggesting the activation of defense-related metabolic pathways. Detailed Implementation
[0028] The present invention will be further described below with reference to specific experimental examples, and the advantages and features of the present invention will become clearer with the description. However, these experimental examples are merely exemplary and do not constitute any limitation on the scope of the present invention. Those skilled in the art should understand that modifications or substitutions to the details and form of the present invention can be made without departing from the spirit and scope of the present invention, but all such modifications and substitutions fall within the protection scope of the present invention.
[0029] Experiment 1: Verification Experiment of the Phase Separation Ability of RsYTHDC Protein and its Key Role in Pathogenesis The encoding gene sequence (SEQ ID No. 2) of Rhizoctonia solani Rsyldica protein (SEQ ID No. 1) was cloned into the pET28a-GFP vector and transformed into Escherichia coli BL21(DE3) competent cells for expression. After induction with 0.5 mM IPTG at 16°C for 18 hours, the soluble His-tagged protein was purified by Ni-NTA affinity chromatography using a 20 mM Tris-HCl and 150 mM NaCl (pH 7.5) purification buffer.
[0030] In in vitro experiments, purified RsYTHDC protein (final concentration 1 μM) was placed in phase separation buffer containing 5% (w / v) PEG 8000 (20 mM Tris-HCl, 150 mM NaCl, pH 7.4) and incubated at room temperature for 10 minutes. The formation of numerous globular protein aggregates was clearly observed under a differential interference contrast microscope. Figure 1 b); Droplet fusion experiments showed ( Figure 1 c) Upon contact, the droplets rapidly coalesced and relaxed into a single near-spherical structure within 50 seconds; their dynamic properties were further analyzed using fluorescence recovery after bleaching (FRAP) technology. Figure 1 After spot photobleaching of a single condensate, its fluorescence signal recovered by more than 60% within 60 seconds, confirming that the formed condensate has typical liquid flow characteristics and belongs to liquid-liquid phase separation.
[0031] To verify its phase separation ability in vivo, the constructed RsYTHDC-GFP fusion expression plasmid was transiently transformed into buckwheat leaf protoplasts via PEG-mediated transformation. Twenty-four hours after transformation, under a confocal microscope, numerous dynamic, droplet-like fluorescent aggregates of RsYTHDC-GFP were observed in the cytoplasm. Figure 2 a). In contrast, the mutant RsYTHDC, which lacks the intrinsic disorder region (PrD) domain, ΔPrD -GFP was uniformly dispersed without aggregate formation, confirming that the PrD domain is essential for phase separation.
[0032] To confirm the direct link between phase segregation ability and pathogenicity, overexpression was performed in Arabidopsis thaliana. RsYTHDC Genes, compared to wild type, are overexpressed RsYTHDC Arabidopsis thaliana (OE-) RsYTHDC Disease resistance was significantly reduced (P<0.01); while overexpression RsYTHDC ΔPrD The mutant Arabidopsis thaliana (OE- RsYTHDC ΔPrD The disease resistance of the genotype was not significantly different from that of the wild type. Figure 2 b). The above results collectively demonstrate that the RsYTHDC protein possesses significant phase separation ability, and that this ability is crucial for its pathogenic function.
[0033] Example 2: Screening, discovery, and binding validation of small molecule inhibitors targeting the RsYTHDC phase separation interface. Based on the pathogenic mechanism of RsYTHDC phase separation elucidated in Experiment Example 1, an integrated computational and experimental screening strategy was adopted to develop its specific inhibitor.
[0034] First, the high-confidence 3D structure of the RsYTHDC protein was predicted using AlphaFold 3 software. By analyzing the surface features of its key phase-separation interface—the YTH domain—a binding pocket containing key residues such as Phe534, Asp537, Tyr589, and Arg631 was defined as a pharmacodynamic pocket for virtual screening. Subsequently, a high-throughput virtual screening of a commercial molecular library containing approximately 1.6 million compounds was performed using the Autodock Vina molecular docking program. The screening criteria were: a docking score (Vina score) < -10.0 kcal / mol, and the ligands must form specific interactions with the aforementioned key residues. After two rounds of increasingly precise docking screening and molecular dynamics simulations (GROMACS software, AMBER99SB-ILDN force field, simulation time 200 ns) to evaluate the binding conformation stability, compound sdf:12041 (chemical name: (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide) was finally ranked as the top candidate lead compound.
[0035] To verify the results of the virtual screening, the binding ability of sdf:12041 to RsYTHDC protein was directly measured using micro-thermophoresis. The purified protein (RsYTHDC-GFP, final concentration 20 nM) was mixed with a series of serially diluted sdf:12041 concentrations (1 nM to 200 μM) in a detection buffer (20 mM HEPES, 150 mM NaCl, 0.05% Tween-20, pH 7.4), and measurements were performed using a Monolith NT.115 instrument. The results showed that the binding of sdf:12041 to RsYTHDC exhibited a significant concentration dependence, and the dissociation constant Kd was found to be 17.51 nM using the instrument's software. Figure 3 c) confirmed that it has strong affinity at the nanomolar level, a result that is highly consistent with the predictions of virtual screening.
[0036] To further confirm the binding specificity of sdf:12041, a point mutant of the YTH domain of RsYTHDC (RsYTHDC) was constructed. mut This mutant alters key residues in the predicted binding pocket. Binding experiments using the same MST method showed a sharp decrease in the binding affinity of sdf:12041 to this mutant protein (Kd = 161.6 nM). Figure 3 d). This control experiment demonstrates that sdf:12041 does indeed specifically bind to the functional interface of the YTH domain of RsYTHDC, which is predicted by computation.
[0037] Through the above-mentioned integrated computational biology and biophysical experimental process, a small molecule inhibitor, sdf:12041, capable of binding to the key interface of RsYTHDC phase separation with high affinity and specificity was successfully screened and identified, laying a solid compound foundation for its subsequent development as a functional inhibitor.
[0038] Experimental Example 3: An experiment based on molecular dynamics simulation to analyze the molecular mechanism by which SDF-12041 inhibits RSYTHDC phase separation. To gain a deeper understanding of the mechanism of action of SDF-12041 at the atomic level, this experiment employed all-atom molecular dynamics simulations. Using GROMACS 2022.3 software, two simulation systems were constructed with the AMBER99SB-ILDN force field: the RsYTHDC protein (unbound ligand) and its complex with SDF-12041. Each system was placed in a cubic periodic box, solvated to a TIP3P water model, and appropriate amounts of sodium and chloride ions were added to neutralize the net charge of the system.
[0039] The simulations first minimized the energy of the system to eliminate unfavorable atomic contacts, followed by a 10 ns equilibrium simulation in the NVT ensemble (constant particle number, volume, and temperature), with temperature coupling using the Berendsen hot bath algorithm (310 K). Next, a 10 ns equilibrium simulation was performed in the NPT ensemble (constant particle number, pressure, and temperature), with pressure coupling at 1 bar. Finally, a 2000 ns production simulation was conducted. All simulations were performed at a step size of 2 fs, and long-range electrostatic interactions were handled using the particle mesh Ewald method.
[0040] Analysis of the obtained simulated trajectories showed that, after combining with sdf-12041, the root mean square deviation of the RsYTHDC protein backbone atoms was significantly reduced, and the protein reached a stable plateau more quickly. Figure 3(b) This indicates that the binding of the sdf-12041 small molecule makes the overall protein conformation more rigid. Secondly, compared to the standalone RsYTHDC protein, the gyration radius of the complex decreased by approximately 0.3 nm, suggesting a shift towards a more compact conformation. Further analysis shows that the sdf-12041 molecule binds to a hydrophobic pocket within the YTH domain of RsYTHDC, forming stable hydrogen bonds and van der Waals interaction networks with key residues such as Phe534, Asp537, Tyr589, and Arg631 (3a). Crucially, this binding significantly weakens the original intramolecular interaction energies between the YTH domain and the PrD2, PrD3, and PrD4 regions. Finally, analysis of seven key interface residues (Phe534, Asp537, Pro540, Pro587, Tyr589, Glu605, Arg631) at the residue level revealed that sdf-12041 can comprehensively reduce the binding strength between these residues and each PrD region.
[0041] The simulation results revealed the mechanism of action of sdf-12041 at the atomic scale: sdf-12041 specifically binds to the YTH domain interface residues of RsYTHDC, disrupting its intramolecular interaction network with PrD2 / 3 / 4, thereby stabilizing the protein's non-phase-separating conformation and ultimately inhibiting its liquid-liquid phase separation ability. This discovery provides solid structural biology evidence for sdf-12041 as a targeted inhibitor of phase separation.
[0042] Experimental Example 4: Evaluation of the detached leaf efficacy, in vivo accumulation, and field efficacy of SDF:12041 1. Experimental Methods Excised leaves from 20-day-old tartary buckwheat (Fagopyrum tataricum) seedlings were pretreated with 0%, 0.1%, 0.5%, and 1% SDF:12041, respectively. After inoculation with R. solani AG4-HGI3 mycelial blocks, the leaves were cultured at 30℃ for 36 hours, and phenotypes were observed (scale bar 1 cm). Untreated (CK) leaves served as the control. Each group had 30 leaves per experiment, and data were obtained from three independent experiments and quantitatively validated. The test was extended to maize (Zea mays), wheat (Triticum aestivum), and barley (Hordeum vulgare). Excised leaves were pretreated with 1% SDF:12041 or water (Mock) before inoculation with the pathogen and cultured for 72 hours. The experiment was independently repeated three times. Disease incidence was expressed as mean ± standard deviation (n ≥ 30 leaves) and quantitatively analyzed. In vivo accumulation was detected by liquid chromatography-mass spectrometry (LC-MS): Soil-grown buckwheat plants were treated with 1% sdf:12041 for 24 hours (Treat) or DMSO was used as a control (CK). The content of sdf:12041 in roots, stems and leaves was determined. Data represent mean ± SD (n=3 biological replicates).
[0043] A field cross-inoculation trial was conducted in Beijing, with a control area (CK, R. solani + 1% DMSO) and a treatment area (sdf:12041 + R. solani). Symptoms were observed and recorded one week after inoculation.
[0044] 2. Experimental Results Phenotypic and quantitative analysis of detached leaf blades showed that ( Figure 4 a, 4b), 0.1%, 0.5%, 1% sdf:12041 pretreatment significantly reduced the infection of tartary buckwheat leaves by R. solani, and the difference was extremely significant compared with CK (** represents P<0.01, *** represents P<0.001, two-tailed Student's t test).
[0045] In maize, wheat, and barley, pretreatment with 1% sdf:12041 also significantly reduced the incidence of disease. Figure 4 (c, 4d) There were highly significant differences between the treatment group and the control group (** represents P<0.01, two-tailed t-test), indicating that sdf:12041 has significant protective efficacy against R. solani leaf infection in gramineous crops.
[0046] LC-MS detection showed that ( Figure 4 e), sdf:12041 was accumulated in the root, stem and leaf tissues of tartary buckwheat, and the difference was extremely significant compared with CK (** represents P<0.01, *** represents P<0.001, two-tailed Student's t test).
[0047] Beijing field cross-inoculation trials showed that ( Figure 4 f), sdf:12041 treatment area showed a significant reduction in damping-off symptoms.
[0048] Experiment 5: Field yield assessment of buckwheat treated with sdf:12041 at two geographical experimental sites. 1. Experimental Methods Yield determinations were conducted at two field trial sites in Haidian District, Beijing, and Zhaotong, Yunnan Province, during the harvest season. Two conditions were established: one without R. solani infection (control group CK and sdf:12041 treatment group) and one with R. solani infection (buffer zone, R. solani treatment group, and sdf:12041+R. solani treatment group), with three biological replicates per treatment. Data are expressed as mean ± standard deviation (SD) (n=3). Two-tailed Student's test was used for comparisons between two groups under the infection-free condition; one-way ANOVA was used for comparisons among multiple groups under the infection condition; and Tukey's HSD test was used for post-hoc multiple comparisons.
[0049] 2. Experimental Results Experimental results showed that, under conditions without R. solani infection, the Beijing site ( Figure 5 a) and Zhaotong, Yunnan ( Figure 5 b) The yield of the sdf:12041 treatment group was not significantly different from that of the respective CK group (ns, two-tailed Student's t test).
[0050] Under R. solani infection conditions, Beijing point ( Figure 5 c) and Zhaotong, Yunnan ( Figure 5 In d), the yields of all R. solani-treated groups were significantly lower than those in the buffer zone; however, the yields of the treatment groups treated with sdf:12041 significantly recovered. Different lowercase letters in the columns indicate significant differences within groups at the P < 0.05 level (Tukey's HSD), indicating that sdf:12041 significantly alleviated the yield inhibition caused by R. solani pathogen. These results confirm that sdf:12041 does not affect the normal yield of buckwheat under field conditions and can effectively compensate for yield losses caused by pathogens.
[0051] Experimental Example 6: Crop Safety Assessment of Compound SDF-12041 1. Experimental Methods To comprehensively evaluate the crop safety of sdf:12041, yield determination and multi-omics analysis were conducted in Haidian District, Beijing and Zhaotong, Yunnan Province at harvest time. Treatment groups and controls (healthy / inoculated) were included, with three replicates. Yield was calculated based on actual harvested area (kg / 10m²). 2 ), record thousand-grain weight and yield per plant, and perform ANOVA + Tukey's HSD test. Another 1% of 12-day-old tartary buckwheat treated with sdf:12041 was sampled and flash-frozen in liquid nitrogen at specified time points: Transcriptome sequencing was performed using the Illumina platform / library preparation kit, compared with the reference genome, |log2FC|≥1 and p<0.05 were used to screen for DEGs, and GO / KEGG were enriched using clusterProfiler; Metabolome analysis was performed using LC-MS / MS / GC-MS / broadly targeted detection, VIP≥1 and p<0.05 were used to screen for DEMs, and KEGG was mapped.
[0052] 2. Experimental Results The yield determination experiment results showed that the crop yield in the sdf-12041 treatment area was not significantly different from that in the healthy control group, while the yield in the disease control group was significantly reduced.
[0053] Tissue distribution analysis showed that sdf-12041 could be systematically transported to roots, stems, and other organs after foliar spraying. Figure 4 e), indicating that it has good internal conductivity.
[0054] Transcriptomic analysis showed that the proportion of gene expression changes induced by sdf-12041 treatment was low, and it was not significantly enriched in key growth-related pathways. Figure 6 ab).
[0055] Furthermore, non-targeted metabolomics analysis (LC-MS) showed that the levels of core metabolites (including sugars, amino acids, organic acids, etc.) in the leaves of the treated crop were highly similar to those in the healthy control group, with a low proportion of differentially metabolites, mainly concentrated in secondary metabolic pathways such as terpenes and lignin, while primary metabolic pathways were not significantly disturbed. Figure 7 ab).
[0056] In summary, compound sdf-12041 can effectively control diseases caused by Rhizoctonia solani under field conditions, while having no adverse effects on crop yield and metabolic homeostasis, demonstrating good safety for agricultural applications.
Claims
1. (3-Bromophenoxy)-N-{8-[2-(3-Bromophenoxy)acetamido]octyl}acetamide in the preparation of antibacterial agents against the pathogenic bacterium Rhizoctonia solani ( Rhizoctonia solani Uses in pesticide formulations for crop sheath blight caused by fungi.
2. The use according to claim 1, characterized in that, The molecular formula of the (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide is C 24 H 29 Br2N2O4, its chemical structural formula is shown in Formula I: Formula I.
3. The use according to claim 1, characterized in that, The aforementioned Rhizoctonia spp. fungus is Rhizoctonia solani (Rhizoctonia solani). Rhizoctonia solani ).
4. The use according to claim 1, characterized in that, The crops mentioned include buckwheat, corn, wheat, or barley.
5. A pesticide composition for combating crop diseases caused by Rhizoctonia solani fungi, characterized in that, It consists of (3-bromophenoxy)-N-{8-[2-(3-bromophenoxy)acetamido]octyl}acetamide and pesticide formulations with an acceptable carrier.
6. The pesticide composition according to claim 5, characterized in that, The carrier is selected from any one or more of wetting and dispersing agents, stabilizers, emulsifiers, thickeners, antifreeze agents, preservatives, disintegrants, binders, or fillers.
7. The pesticide composition according to claim 6, characterized in that, It is prepared into various pesticide formulations using conventional methods for pesticide formulation.
8. The pesticide composition according to claim 7, characterized in that, The pesticide formulations mentioned include emulsifiable concentrates, suspensions, wettable powders, water-dispersible granules, microemulsions, water-in-oil emulsions, oil suspensions, or emulsifiable concentrates.
9. The pesticide composition according to claim 5, characterized in that, The aforementioned Rhizoctonia spp. fungus is Rhizoctonia solani (Rhizoctonia solani). Rhizoctonia solani ).
10. The pesticide composition according to claim 5, characterized in that, The crops mentioned include buckwheat, corn, wheat, or barley.
